About: Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
Creator	Carugati, Manuela Ormas, Valentina Pozzetti, Ugo Piconi, Stefania Castaldo, Gioacchino Faccioli, Paolo Franzetti, Marco Iemoli, Enrico Longoni, Ernesto Molteni, Chiara Pandolfo, Alessandro
Source	Elsevier; Medline; PMC
abstract	Abstract We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.
has issue date	2020-05-16(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.05.050
bibo:pmid	32422376
has license	els-covid
sha1sum (hex)	4a459b10ba9b140c9c8e89891a97f42f8a9a10da
schema:url	https://doi.org/10.1016/j.ijid.2020.05.050
resource representing a document's title	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
has PubMed Central identifier	PMC7228890
has PubMed identifier	32422376
schema:publication	Int J Infect Dis
resource representing a document's body	covid:4a459b10ba9b140c9c8e89891a97f42f8a9a10da#body_text
is schema:about of	named entity 'promising' named entity 'COVID-19' named entity 'needed' named entity 'severe' named entity 'The' named entity 'Further' named entity 'studies' named entity 'confirm' named entity 'efficacy' named entity 'safety' named entity 'Center' named entity 'profile' named entity 'Coronavirus disease 2019' named entity 'short half-life' named entity 'immunomodulatory' named entity 'Coronavirus disease 2019' named entity 'parenchymal' named entity 'interstitial fibrosis' named entity 'ceftriaxone' named entity 'coronavirus disease 2019' named entity 'tocilizumab' named entity 'causal inference' named entity 'azithromycin' named entity 'venous thromboembolism' named entity 'remdesivir' named entity 'ceftriaxone' named entity 'psychiatric evaluation' named entity 'tocilizumab' named entity 'subacute care' named entity 'immunomodulatory' named entity 'inflammation' named entity 'monocytes' named entity 'infection' named entity 'anti-thrombotic' named entity 'pro-inflammatory cytokines' named entity 'tobacco smoke' named entity 'immune dysregulation' named entity 'CT angiogram' named entity 'TNF-α' named entity 'Ectasia' named entity 'SARS-CoV-2' named entity 'lung consolidation' named entity 'respiratory function' named entity 'body temperature' named entity 'inflammatory markers' named entity 'electrocardiogram' named entity 'nucleic acid amplification test' named entity 'CD14' named entity 'COVID' named entity 'COVID-19' named entity 'written consent' named entity 'Italy' named entity 'pharyngeal' named entity 'supplemental oxygen' named entity 'D-dimer' named entity 'ventilatory support' named entity 'assay' named entity 'lung disease' named entity 'C-reactive protein' named entity 'asthenia' named entity 'intravenously' named entity 'viruses' named entity 'C-reactive protein' named entity 'oxygen saturation' named entity 'inflammatory mediator' named entity 'immunomodulatory agent' named entity 'oxygen saturation' named entity 'antiviral therapy' named entity 'subpleural' named entity 'subcutaneously' named entity 'pharyngeal'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software